The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injections as an add-on therapy for adults with chronic obstructive pulmonary disease (COPD) who continue to struggle ...

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

At that time Sanofi was cruising towards an important FDA approval for its Dupixent (dupilumab) injection for the skin disease also known as atopic dermatitis. Noting the blockbuster potential for ...

randomized to 300 mg of subcutaneous dupilumab or a placebo injection every 2 weeks. At 36 weeks, 20% of those treated with dupilumab achieved the primary endpoint of sustained disease remission ...

"After the third injection of dupilumab, the patient was free of symptoms (no new wheals or angioedema; UCT = 16)," the case authors reported. She remained symptom-free and was able to discontinue ...

and Sanofi today presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent ® (dupilumab) in adults with moderate-to-severe bullous ...

Perspective from John Luo, MD Patients with dupilumab prescriptions for their atopic dermatitis had lower risks for psychiatric and sleep disorders than those prescribed other treatments ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab was able to improve lichenification among patients aged 6 to 88 years with atopic dermatitis.

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a supplemental Biologics License Application for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP), a ...

1 Dupilumab is being jointly developed by Regeneron ... Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection).

1 Dupilumab is being jointly developed by Regeneron and Sanofi ... Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection). Your ...